5.250USD-0.94%Mkt Cap: 28.32M USDP/E: —Last update: 2026-06-01
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap28.32M USD
Enterprise Value9.29M USD
Revenue (TTM)-13.27K USD
Gross Profit-13.27K USD
Net Income (TTM)-17.43M USD
Revenue/Share-0.0040 USD
Last Price5.250 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.19
PEG—
EV/EBITDA-0.66
EV/Revenue-700.36
P/S-2163.12
P/B0.96
EPS (TTM)-7.90
EPS (Forward)-2.43
52W Range
3.6459% of range21.40
52W High21.40 USD
52W Low3.645 USD
Profitability
Gross Margin0.00%
Oper. Margin110513.32%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-62.90%
ROA-27.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.68M USD
CapEx (TTM)—
FCF Margin77024.19%
FCF Yield-36.08%
Net Debt-19.41M USD
Net Debt/EBITDA1.39
Balance Sheet
Debt/Equity0.02
Current Ratio14.31
Quick Ratio13.91
Book Value/Sh5.523 USD
Cash/Share3.597 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateDec 24, 2024
Analyst Consensus
Rating3.0 (Hold)
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.5.40M
Float4.19M
Insiders7.70%
Institutions55.03%
Short Interest
Short Ratio0.7d
Short % Float0.36%
Short % Out.0.36%
Shares Short19.60K
Short (prev mo.)23.31K
Technical
SMA 504.841 (+8.5%)
SMA 2006.409 (-18.1%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)40.29K
Avg Vol (10d)65.81K
Technical Indicators
RSI (14)57.1
MACD0.1074
MACD Signal0.0910
MACD Hist.+0.0164
BB Upper5.643 USD
BB Middle5.161 USD
BB Lower4.680 USD
BB Width18.66%
ATR (14)0.2742 USD
Vol Ratio (20d)0.41x